Sorrento Therapeutics, Inc.
(NASDAQ : SRNE)

( )
SRNE After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -0.10%159.870.0%$1295.48m
AMGNAmgen, Inc. 2.21%255.131.3%$694.68m
SNSSSunesis Pharmaceuticals, Inc. 1.90%8.030.7%$561.33m
NVAXNovavax, Inc. 0.37%202.0980.0%$556.50m
ILMNIllumina, Inc. 0.98%401.963.5%$517.94m
GILDGilead Sciences, Inc. 0.72%65.771.0%$463.29m
REGNRegeneron Pharmaceuticals, Inc. 2.80%494.642.7%$449.68m
VRTXVertex Pharmaceuticals, Inc. 1.83%221.101.9%$383.88m
ALXNAlexion Pharmaceuticals, Inc. 1.45%157.542.0%$298.86m
BNTXBioNTech SE 6.12%140.720.0%$266.37m
BIIBBiogen, Inc. 1.75%270.441.7%$264.45m
EXASEXACT Sciences Corp. 2.66%130.5218.4%$192.20m
NBIXNeurocrine Biosciences, Inc. -0.05%95.004.9%$177.73m
CRSPCRISPR Therapeutics AG 0.60%123.850.6%$174.50m
SGENSeagen Inc. 3.77%149.645.8%$153.69m

Company Profile

Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates. It operates through Sorrento Therapeutics and Scilex segments. The company was founded by Henry H. Ji in 2006 and is headquartered in San Diego, CA.